Corbus Pharmaceuticals Holdings Inc. closed $42.39 short of its 52-week high ($61.90), which the company reached on July 31st ...

Corbus Pharmaceuticals and Novo Nordisk stocks plunge following cannabinoid receptor drug trials, raising concerns over ...

Novo Nordisk stock tumbled Friday — pulling Corbus into a steep dive — after its new obesity drug caused neuropsychiatric side effects.

Why Corbus Pharmaceuticals sees Novo Nordisk’s controversial approach to obesity drugs as a ticket to a blockbuster.

The Federal Reserve yesterday cut interest rates by 50 basis points, in its first time cutting rates in four years. And how ...

Novo Nordisk announced positive Phase 2a trial results for monlunabant, showing significant weight loss with a 10 mg dose.

Novo Nodrisk’s cannabinoid receptor–targeting obesity pill was picked up in the $1.1 billion acquisition of Inversago ...

The release of OpenAI‘s ChatGPT chatbot in November 2022 unleashed a frenzy of investor interest in artificial intelligence ...

Mizuho Securities analyst Graig Suvannavejh has reiterated their bullish stance on CRBP stock, giving a Buy rating on August 28. Graig ...

Aug. 06, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today provided a corporate update and reported financial results for the ...

This was the stock's third consecutive day of losses.